ArticleJournal of managed care & specialty pharmacy2023
Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis.
Article in Journal of managed care & specialty pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 13 citations in OpenAlex.
- Estimating the Healthcare Cost of Infection-Related Hospitalisations in Multiple Myeloma.PharmacoEconomics · 2026Article
- Article
- Burden of Disease, Treatment Patterns, and Healthcare Resource Utilization in Multiple Myeloma in the Middle East and North Africa Region: A Targeted Literature Review.Oncology and therapy · 2026Review
- Burden of Treatment, Treatment Sequencing and Healthcare Resource Utilization in Multiple Myeloma in Latin America: A Targeted Literature Review.Oncology and therapy · 2026Review
- Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies.Journal of managed care & specialty pharmacy · 2026Article
- Cost-Effectiveness Analysis of Daratumumab Monotherapy and Subsequent Therapies in Heavily Treated Relapsed/Refractory Multiple Myeloma: A Feasible Methodology using a Korean Nationwide Population Cohort.Cancer research and treatment · 2026Article
- Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1-3 Prior Lines of Therapy: Optum Database.Cancer medicine · 2025Article
- Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation antigen-targeted therapies.Future oncology (London, England) · 2025Article
- Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies.Current hematologic malignancy reports · 2025Review
- Gut microbiota in immunomodulation and infection prevention among multiple myeloma patients after chemotherapy: current evidence and clinical prospects.American journal of cancer research · 2025Review
- Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Health care resource utilization and costs of Medicare-enrolled patients with HR+/HER2- metastatic breast cancer treated with a CDK4/6i in the first-line setting.Journal of managed care & specialty pharmacy · 2025Article
- From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population.Oncology and therapy · 2024Article
- Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies.Blood advances · 2024Article
- Article
- Central nervous system-active medication polypharmacy and risk for nursing home admission among adults with early-onset dementia: A retrospective cohort study.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.